DM Bio Changes Company Name to STGen Bio

[Asia Economy Reporter Chunhee Lee] DM Bio, a contract manufacturing organization (CMO) specializing in biopharmaceutical production under Dong-A Socio Holdings Group, will change its name to STGEN BIO.

DM Bio announced on the 28th that it will change its name to STGEN BIO starting next month on the 1st. This name change follows the diversification of DM Bio's business and the unification of the governance structure under Dong-A Socio Holdings. Established in 2015 as a joint venture between Dong-A Socio Holdings and Japan's Meiji Seika Pharma, DM Bio's governance was unified last October when Dong-A Socio Holdings acquired Meiji Seika Pharma's shares.

The name 'STGEN' in STGEN BIO stands for 'Science Technology Gene,' emphasizing Dong-A Socio Group's commitment to strengthening its capabilities within the bio industry and clarifying the company's future vision and goals.

STGEN BIO currently distributes commercialized products in the domestic and Japanese markets and manufactures and supplies raw materials and finished biopharmaceuticals for clinical trials in Europe and the United States. The company has also secured orders for two biosimilar antibody products aimed at global market entry and is conducting verification batch production. The company aims to commence full-scale commercial production next year.

Additionally, STGEN BIO is expanding its business scope to contract development (CDO) and is preparing to become a global CDMO (contract development and manufacturing organization) company.

Choi Kyung-eun, CEO of STGEN BIO, stated, “We plan to diversify our business from producing biopharmaceuticals centered on single antibodies and recombinant proteins to next-generation modality drugs such as gene and cell therapies (CGT). We will not merely change the company name but, through ongoing projects, become STGEN BIO, a global CDMO company taking a significant leap forward.”

This content was produced with the assistance of AI translation services.